发文地区与机构
近年国家 / 地区发文量统计
| 国家 / 地区 | 发文量 |
|---|---|
| USA | 690 |
| England | 235 |
| CHINA MAINLAND | 151 |
| Canada | 135 |
| GERMANY (FED REP GER) | 103 |
| Netherlands | 102 |
| Italy | 94 |
| South Korea | 76 |
| Japan | 75 |
| France | 63 |
近年机构发文量统计
| 机构 | 发文量 |
|---|---|
| HARVARD UNIVERSITY | 117 |
| UNIVERSITY OF TORONTO | 78 |
| UNIVERSITY OF LONDON | 67 |
| UNIVERSITY OF CALIFORNIA SYSTEM | 61 |
| DANA-FARBER CANCER INSTITUTE | 54 |
| UNIVERSITY OF TEXAS SYSTEM | 54 |
| MEMORIAL SLOAN KETTERING CANCER CENTER | 49 |
| BRIGHAM & WOMEN'S HOSPITAL | 45 |
| MASSACHUSETTS GENERAL HOSPITAL | 44 |
| UNIVERSITY OF NOTTINGHAM | 44 |
文章引用情况
1
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients2
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer3
GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer4
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker5
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2-advanced breast cancer in the randomized MONALEESA-2 trial6
High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival7
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials8
Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance9
Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-201310
Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer